Shanghai Laishi (002252.SZ): “SR604 injection” enters phase III clinical trial

Zhitong Finance App News, Shanghai Laishi (002252.SZ) issued an announcement. The company's product “SR604 Injection” recently publicized the “Prevention and Treatment of Hemorrhagic Attacks in Hemophilia A/B Patients” phase III clinical trial registration information on the drug clinical trial registration and information disclosure platform of the State Drug Administration. Test name: Evaluating the efficacy and safety of SR604 injection in hemophilia A/B patients with or without inhibitors. The purpose of the single-arm, multi-center phase III clinical trial is to evaluate the efficacy and safety of SR604 injections in hemophilia A/B patients with or without inhibitors. The effectiveness of preventive treatment in /B patients.

Based on the early exploration of SR604 injections in multiple doses and administration cycles for hemophilia A/B, the company is now carrying out a phase III confirmatory clinical study on the prevention and treatment of hemorrhagic attacks in patients with hemophilia A/B. It is proposed to conduct multiple administration tests with 0.4 mg/kg dosing every 4 weeks. If successfully developed, this variety is expected to significantly improve the medication experience of patients with haemophilia A/B. As of the date of disclosure of the announcement, no products targeting the same target as this drug have been marketed globally.